Table 1 Baseline patient characteristics (N = 1304 intension-to-treat population)

From: Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study

Total number

 

6M group

12M group

  

n = 654

n = 650

Nodal status

N1

504 (77.1%)

498 (76.6%)

 

N2/N3

150 (22.9%)

152 (23.4%)

Gender

Male

352 (53.8%)

343 (52.8%)

 

Female

302 (46.2%)

307 (47.2%)

Age

<70

451 (69.0%)

442 (68.0%)

 

70

203 (31.0%)

208 (32.0%)

Tumour location

Right-sided colon (C/A/T)

262 (40.1%)

263 (40.5%)

 

Left-sided colon (D/S)

258 (39.4%)

252 (38.8%)

 

Rectosigmoid colon

134 (20.5%)

135 (20.8%)

Surgical approach

Laparoscopic

276 (42.2%)

255 (39.2%)

 

Open(conventional)

378 (57.8%)

395 (60.8%)

Histological type

Pap/ Well

189 (28.9%)

178 (27.4%)

 

Tub/Mod

419 (64.1%)

433 (66.6%)

 

Poor/Solid/Mon-solid/Muc/Sig/Other

46 (7.0%)

39 (6.0%)

T(TMN 7th)

T1/T2

101 (15.4%)

100 (15.4%)

 

T3

366 (56.0%)

363 (55.8%)

 

T4

187 (28.6%)

187 (28.8%)

N (TNM 7th)

N1

512 (78.3%)

506 (77.8%)

 

N2

142 (21.7%)

144 (22.2%)

Stage (TNM 7th)

IIIA

94 (14.4%)

96 (14.8%)

 

IIIB

461 (70.5%)

458 (70.5%)

 

IIIC/IVA/IVB

99 (15.1%)

96 (14.8%)